This research project will study the role of epigenetic DNA regulation, and specifically of Cytosine methylation, in normal B-cell development and lymphomagenesis. The long-term objective for the project is to be able to subclassify the heterogeneous group of Diffuse Large B-cell Lymphomas (DLBCL) based on gene methylation signature into clinically relevant groups and to identify patients, which will be responsive to standard therapy and epigenetic therapy including demethylating agents.
The specific aims i nclude: a) identifying the epigenomic signatures in DLBCLs and subsets of normal B cells using DNA methylation and gene expression profiling, using epigenomic signatures to classify DLBCLs into prognostically and biologically relevant groups;b) identifying the molecular mechanism of normal and aberrant B-cell DNA methylation dependent gene silencing by studying the expression and biological functions of DNA methyltransferases and Methyl Binding proteins;identifying epigenomic signatures predictive of biological dependence on these factors and predictive of response to epigenetic therapy drugs, and testing the therapeutic value of targeting DNMTs and MBDs by using shRNA and small molecules in DLBCL cell lines and primary patient samples. The data will lead to predictive models of clinical and biological behavior of DLBCLs based on the integration of gene expression and epigenetic signatures, will identify epigenomic prognostic markers, identify genes and biological pathways which are responsible for neoplastic transformation of normal lymphocytes and will test the suitability of the epigenetic silencing machinery as potential therapeutic targets in DLBCL, which are most common and biologically heterogeneous group of lymphomas.

Public Health Relevance

to Public Health: This research project will study contribution of non-inheritable DNA modifications to the pathobiology of Lymphomas. We will identify prognostic markers in Diffuse Large B-cell Lymphomas, subclassify lymphomas based on epigenetic signatures and test novel therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA127353-05
Application #
8316330
Study Section
Subcommittee G - Education (NCI)
Program Officer
Perkins, Susan N
Project Start
2008-09-01
Project End
2013-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$138,672
Indirect Cost
$10,272
Name
Weill Medical College of Cornell University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Chambwe, Nyasha; Kormaksson, Matthias; Geng, Huimin et al. (2014) Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood 123:1699-708
Jiang, Yanwen; Hatzi, Katerina; Shaknovich, Rita (2013) Mechanisms of epigenetic deregulation in lymphoid neoplasms. Blood 121:4271-9
Clozel, Thomas; Yang, ShaoNing; Elstrom, Rebecca L et al. (2013) Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov 3:1002-19
Shaknovich, Rita; Cerchietti, Leandro; Tsikitas, Lucas et al. (2011) DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood 118:3559-69
Oricchio, Elisa; Nanjangud, Gouri; Wolfe, Andrew L et al. (2011) The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 147:554-64
Shaknovich, Rita; Melnick, Ari (2011) Epigenetics and B-cell lymphoma. Curr Opin Hematol 18:293-9
Shaknovich, Rita; Geng, Huimin; Johnson, Nathalie A et al. (2010) DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood 116:e81-9
Peled, Jonathan U; Yu, J Jessica; Venkatesh, Jeganathan et al. (2010) Requirement for cyclin D3 in germinal center formation and function. Cell Res 20:631-46